Ebola Outbreak in Uganda: Part 1 Background

In 2012, in the Luwero District of central Uganda, Dr. Innocent treated Ebola patients under austere conditions with extremely limited resources. In this video, he sets the background, describing the Ugandan health care system and events leading up to the outbreak.

Ebola Outbreak in Uganda: Part 2 Ebola Case Study
▶︎

Ebola Outbreak in Uganda: Part 2 Ebola Case Study

Ebola Survivor - Dr. Ian Crozier
▶︎

Ebola Survivor - Dr. Ian Crozier

Ebola Outbreak in Uganda: Part 3 Question and Answer
▶︎

Ebola Outbreak in Uganda: Part 3 Question and Answer

FDA Direct: No One Think It's a Good Idea for Kids to Consume Petroleum Products
▶︎

FDA Direct: No One Think It's a Good Idea for Kids to Consume Petroleum Products

AGDD 2025 | D2S03 - Common Deficiencies and Resolutions: Complex Drug Substance/Excipients/Products
▶︎

AGDD 2025 | D2S03 - Common Deficiencies and Resolutions: Complex Drug Substance/Excipients/Products

FDA Direct: The Power of Real-Time Clinical Trials
▶︎

FDA Direct: The Power of Real-Time Clinical Trials

FDA Grand Rounds - Clinical Omics Biomarker Discovery and Validation in Precision Medicine
▶︎

FDA Grand Rounds - Clinical Omics Biomarker Discovery and Validation in Precision Medicine

FDA Direct - Special Edition of FDA Direct
▶︎

FDA Direct - Special Edition of FDA Direct

193rd Vaccines and Related Biological Products Advisory Committee Meeting
▶︎

193rd Vaccines and Related Biological Products Advisory Committee Meeting

FDA Direct: Who Buys the Spin — Hook, Line and Sinker?
▶︎

FDA Direct: Who Buys the Spin — Hook, Line and Sinker?

CDER & CBER All Hands: Implementing the FDA's Plausible Mechanism Framework
▶︎

CDER & CBER All Hands: Implementing the FDA's Plausible Mechanism Framework

FDA Direct, Striking a Balance - Framework for Future Covid-19 Vaccine Decisions
▶︎

FDA Direct, Striking a Balance - Framework for Future Covid-19 Vaccine Decisions

FDA Webinar: Safety Assessment of Genome Editing in Gene Therapy
▶︎

FDA Webinar: Safety Assessment of Genome Editing in Gene Therapy

FDA Direct: What's the Deal with Talc? - Recapping
▶︎

FDA Direct: What's the Deal with Talc? - Recapping

AGDD 2025 | D1S02 - Novel Bioequivalence Study Design Recommendations
▶︎

AGDD 2025 | D1S02 - Novel Bioequivalence Study Design Recommendations

Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic aci...
▶︎

Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic aci...

Financial Transparency & Efficiency of the Prescription Drug, Biosimilar, & Generic Drug User Fees
▶︎

Financial Transparency & Efficiency of the Prescription Drug, Biosimilar, & Generic Drug User Fees

FDA Direct: Combating Rare Diseases at the FDA
▶︎

FDA Direct: Combating Rare Diseases at the FDA

FDA Direct: FDA is Not Your Doctor - Discussing FDA's Role and Mandate
▶︎

FDA Direct: FDA is Not Your Doctor - Discussing FDA's Role and Mandate

Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers
▶︎

Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers